Bio-Techne Corporation — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2023, compared with fiscal 2022. The request metadata says “2022 Q4,” but the filing is a fiscal 2023 annual report, not a standalone quarterly report.
Business context
Bio-Techne develops and sells life-science reagents, instruments and services for research, diagnostics and bioprocessing markets. Its segments are Protein Sciences (about 74% of fiscal 2023 sales) and Diagnostics and Genomics (about 26%).
Financial performance
| Metric | FY2023 | FY2022 |
|---|---|---|
| Net sales | $1,136.7 million | $1,105.6 million |
| Organic sales growth | 5% | 17% |
| GAAP gross margin | 67.7% | 68.4% |
| Operating income | $298.9 million | $296.6 million |
| Net earnings attributable to Bio-Techne | $285.3 million | $272.1 million |
| Diluted EPS | $1.76 | $1.66 |
| Adjusted net earnings attributable to Bio-Techne | $321.5 million | $323.5 million |
| Adjusted diluted EPS | $1.99 | $1.97 |
| Cash from operations | $254.4 million | $325.3 million |
| Cash, cash equivalents and available-for-sale investments | $204.3 million | $247.0 million |
| Revolver borrowings at June 30 | $350.0 million | $255.9 million |
Revenue rose 3% overall, with 5% organic growth offset by 2% unfavorable currency translation; acquisitions had an immaterial impact. Protein Sciences sales increased 2% and Diagnostics and Genomics sales increased 6%. Consumables grew, while instrument revenue declined. Segment gross margins were 75.3% for Protein Sciences and 61.2% for Diagnostics and Genomics.
GAAP earnings benefited from $49.3 million of net investment gains, primarily the $37.2 million gain on sale of ChemoCentryx and $11.7 million gain on sale of Eminence. Adjusted net earnings declined about 1%. Operating cash flow fell by $70.9 million, which management attributed mainly to earnings and timing changes in operating assets and liabilities.
Material changes, capital and liquidity
- Cash and short-term investments fell to $204.3 million. The company reported $350 million drawn on its $1 billion revolving facility at June 30, leaving $650 million available. It reported $490 million drawn as of August 18, 2023.
- Fiscal 2023 investing included $101.2 million, net of cash acquired, for Namocell and $232 million for a 19.9% Wilson Wolf stake. The filing describes a future purchase of the remaining Wilson Wolf interest for approximately $1 billion, subject to the contract terms and potential acceleration based on performance milestones.
- Bio-Techne paid $50.3 million in dividends and repurchased $19.6 million of shares in fiscal 2023. The board gives no assurance dividends will continue at the same level.
- Fiscal 2024 capital expenditures were planned at approximately $65 million to expand capacity; management expected to fund operations, capital needs and dividends from available funds, the credit facility and operating cash flow for at least the next 12 months.
- After year-end, on July 7, 2023, the company completed its acquisition of Lunaphore for approximately $165 million, net of cash acquired.
Outlook, risks and unusual items
- No specific consolidated revenue or earnings guidance is provided in the supplied filing text. Management cites continued investment in innovation, geographic expansion, acquisitions, and talent development as long-term growth priorities.
- Key risks include economic and research-funding conditions, pricing and competition, foreign exchange, acquisition integration and goodwill impairment, supply-chain and manufacturing disruptions, cybersecurity and privacy compliance, and extensive FDA, laboratory and other regulatory requirements.
- Fiscal 2023 gross margin was pressured by currency and strategic growth investments, including Namocell. Foreign currency translation reduced revenue by approximately $21 million.
- Fiscal 2022 included a full impairment of Eminence goodwill and intangible assets, plus inventory and fixed-asset impairments; the company sold its remaining Eminence shares in fiscal 2023.
- Wilson Wolf’s future purchase obligation is a significant capital commitment. Its second purchase stage is expected between fiscal 2026 and fiscal 2028 under the disclosed terms and could be accelerated if specified milestones are met.
- KPMG issued unqualified opinions on the financial statements and internal control over financial reporting; management also concluded disclosure controls were effective.
Important facts for investors to verify
- Reconcile the period: this filing covers the fiscal year ended June 30, 2023, rather than 2022 Q4.
- Assess underlying earnings excluding investment gains and compare GAAP with the company’s non-GAAP adjustments.
- Monitor operating cash flow, working-capital movements and the change in cash and short-term investments.
- Review the Wilson Wolf agreement’s milestones, timing and approximately $1 billion potential future payment, alongside the company’s borrowing needs.
- Track Namocell and Lunaphore integration, segment growth and margin trends, and the expected return on growth investments.
- Evaluate foreign-exchange exposure, diagnostic reimbursement and regulatory developments, and the company’s exposure to cyber, supply-chain and manufacturing disruptions.